ARTICLE | Clinical News
Dupilumab: Phase III data
June 27, 2016 7:00 AM UTC
The double-blind, international Phase III LIBERTY AD CHRONOS trial in 740 patients with inadequately controlled moderate to severe atopic dermatitis showed that 300 mg subcutaneous dupilumab once week...